Laboratory of Molecular Virology, International Center for Genetic Engineering and Biotechnology, Trieste, Italy.
Front Cell Infect Microbiol. 2018 Nov 12;8:398. doi: 10.3389/fcimb.2018.00398. eCollection 2018.
Classical antiviral therapy targets viral functions, mostly viral enzymes or receptors. Successful examples include precursor herpesvirus drugs, antiretroviral drugs that target reverse transcriptase and protease, influenza virus directed compounds as well as more recent direct antiviral agents (DAA) applied in the treatment of hepatitis C virus (HCV). However, from early times, the possibility of targeting the host cell to contain the infection has frequently re-emerged as an alternative and complementary antiviral strategy. Advantages of this approach include an increased threshold to the emergence of resistance and the possibility to target multiple viruses. Major pitfalls are related to important cellular side effects and cytotoxicity. In this mini-review, the concept of host directed antiviral therapy will be discussed with a focus on the most recent advances in the field of Flaviviruses, a family of important human pathogens for which we do not have antivirals available in the clinics.
经典的抗病毒疗法针对病毒功能,主要是病毒酶或受体。成功的例子包括前体疱疹病毒药物、针对逆转录酶和蛋白酶的抗逆转录病毒药物、针对流感病毒的化合物以及最近应用于丙型肝炎病毒 (HCV) 治疗的直接抗病毒药物 (DAA)。然而,从早期开始,靶向宿主细胞以控制感染作为替代和互补的抗病毒策略的可能性就经常重新出现。这种方法的优点包括增加了出现耐药性的阈值,并且有可能针对多种病毒。主要的缺陷与重要的细胞副作用和细胞毒性有关。在这篇迷你综述中,将讨论宿主定向抗病毒疗法的概念,重点介绍黄病毒领域的最新进展,黄病毒是一组重要的人类病原体,我们目前在临床上还没有可用的抗病毒药物。